Identifying Good Prognosis Subtype in Estrogen Receptor Negative Breast Cancer
Author Information
Author(s): Teschendorff Andrew E, Miremadi Ahmad, Pinder Sarah E, Ellis Ian O, Caldas Carlos
Primary Institution: Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute
Hypothesis
Can we identify molecular subclasses and prognostic markers in estrogen receptor-negative breast cancer?
Conclusion
ER-negative basal breast cancer is heterogeneous with at least four main subtypes, and the variability in clinical outcomes is related to the expression levels of immune response pathway genes.
Supporting Evidence
- A subclass of basal tumors characterized by over-expression of immune response genes has a better prognosis than other ER-negative breast cancers.
- Downregulation of the immune response module confers greater risk for distant metastasis.
- The majority of prognostic markers in ER-negative breast cancer are over-expressed in the good prognosis group.
Takeaway
Some types of breast cancer that don't have estrogen receptors can be grouped into different categories, and some of these groups have a better chance of survival because they show more immune response.
Methodology
A feature selection method was applied to analyze three major microarray expression datasets to identify molecular subclasses and prognostic markers.
Potential Biases
Potential biases may arise from the selection of datasets and the methodology used for feature selection.
Limitations
The study's findings may not be generalizable to all ER-negative breast cancer patients due to the specific datasets used.
Participant Demographics
The study involved 186 ER-negative breast cancer samples.
Statistical Information
P-Value
0.009
Confidence Interval
1.2-3.4
Statistical Significance
p=0.009
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website